FBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.

Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte Biosciences shares for $77 per share in cash.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash.Halper Sadeh encourages Forte shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Forte and its board of directors violated the federal s.

MILWAUKEE, July 27, 2026 /PRNewswire/ -- Ademi LLP is investigating Forte (Nasdaq: FBRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with argenx. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.

Belgian-Dutch immunology company argenx ​will buy ‌Forte Biosciences to add experimental ​autoimmune drug ​FB102 to its portfolio, ⁠the company ​said on ​Monday.

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.

Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results.

Forte Biosciences (FBRX) offers upside as FB102 demonstrates efficacy in both celiac disease and vitiligo, suggesting platform potential beyond a single indication. FB102's mechanism targets CD122, modulating key immune pathways, with placebo-controlled data showing 21.7% F-VASI benefit in vitiligo and histologic protection in celiac disease. FBRX holds a pro forma cash position of ~$220M post-financing, providing 11–12 quarters of runway to advance Phase II/III trials across multiple autoimmune indications.

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript